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AbstrACt
background We report the clinical activity and safety of 
bintrafusp alfa, a first- in- class bifunctional fusion protein 
composed of the extracellular domain of the transforming 
growth factor β (TGF-β)RII receptor (a TGF-β ‘trap’) 
fused to a human IgG1 monoclonal antibody blocking 
programmed death- ligand 1 (PD- L1), in patients with 
heavily pretreated squamous cell carcinoma of the head 
and neck (SCCHN).
Methods In this phase I dose- expansion cohort, patients 
with advanced SCCHN not amenable to curative therapy 
that progressed/recurred after platinum therapy in the 
recurrent/metastatic setting, or <6 months after platinum 
therapy in the locally advanced setting, received bintrafusp 
alfa 1200 mg intravenously every 2 weeks. The primary 
endpoint was confirmed best overall response (BOR; 
Response Evaluation Criteria for Solid Tumors (RECIST) 1.1) 
per independent review committee (IRC); other endpoints 
included BOR per investigator and safety.
results As of August 24, 2018, 32 patients had received 
bintrafusp alfa (median follow- up 86.4 weeks; range 
2–97). Per IRC, the confirmed objective response rate 
(ORR) was 13% (95% CI 4% to 29%; 4 partial responses 
(PR)); 4 patients had stable disease (SD) (disease control 
rate 25%; 95% CI 12% to 43%). Per investigator, there 
were 5 PRs (ORR, 16%), including 2 patients who 
developed delayed PRs after initial disease increase (total 
clinical response rate 22%). Responses (ORRs) were 
observed in patients with PD- L1- positive (12%), PD- L1- 
negative (17%; 73-10 antibody for immunohistochemistry), 
human papillomavirus (HPV)- positive (33%) and HPV- 
negative tumors (5%). Grade 3 treatment- related adverse 
events (TRAEs) were reported in 11 patients (34%), with no 
grade 4 TRAEs or treatment- related deaths.
Conclusions Bintrafusp alfa showed clinical activity 
across subgroups of PD- L1 expression and in HPV- positive 
tumors and had a manageable safety profile in patients 
with heavily pretreated advanced SCCHN. Activity in HPV- 
positive tumors is favorable compared with historical data 
from PD- L1 inhibitors and is being further investigated in 
an ongoing study of HPV- associated tumors.
trial registration number NCT02517398.
bACkground
Squamous cell carcinoma of the head and 
neck (SCCHN) causes nearly 300 000 deaths 
per year as of 2012.1 Smoking, alcohol use 
and infection with human papillomavirus 
(HPV) are leading risk factors for SCCHN.2 3 
Patients with advanced or recurrent SCCHN 
have a poor prognosis and a median overall 
survival (OS) of <1 year in the first- line 
setting, and an even lower median OS in 
the second- line or later- line settings.4–7 OS 
results from KEYNOTE-048 (NCT02358031) 
support the use of pembrolizumab plus 
a platinum agent and 5- fluorouracil or as 
monotherapy in patients with combined posi-
tive score (CPS) >1, as a frontline regimen 
for patients with recurrent/metastatic 
disease.6 8 9 Patients who experience progres-
sion on cetuximab with chemotherapy have 
few treatment options, with low response 
rates (<15%)10 11 and response durability 
or disease stabilization rarely exceeding 3 
months.12–15 Patients with advanced SCCHN 
that progressed within 6 months after the 
last dose of platinum- based therapy in either 
the locally advanced or recurrent/metastatic 
setting have aggressive tumor biology and 
a poor prognosis and represent an unmet 
clinical need.8 9 16 Anti- programmed cell 
death protein 1 (anti- PD-1) immune check-
point inhibitors, including nivolumab and 
pembrolizumab, have shown clinical activity 
in the second- line setting for the treatment 
of SCCHN—objective response rates (ORRs) 
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treatment of patients with SCCHN who experienced 
disease progression on or after platinum- containing 
chemotherapy.
Transforming growth factor β (TGF-β) signaling is 
implicated in multiple tumorigenic processes, including 
immune- related and non- immune- related pathways. 
TGF-β is overexpressed in multiple tumor types and can 
have suppressive effects in early stages of tumorigen-
esis; however, in the tumor microenvironment, TGF-β 
loses its antiproliferative, tumor- suppressing activity and 
instead promotes tumor progression via processes such 
as immune evasion and epithelial- to- mesenchymal tran-
sition (EMT), once a malignancy has been established.18 
Although TGF-β is integral in mediating immune self- 
tolerance in normal tissues,18 its immunosuppressive 
activities assist in immune evasion of tumor cells, and 
TGF-β inhibition can facilitate T- cell invasion in the 
tumor microenvironment and increase susceptibility to 
anti- PD-1/programmed death- ligand 1 (PD- L1) therapy 
in mouse tumor models.19 20 Furthermore, TGF-β can 
promote drug resistance and metastasis via increased 
fibrosis, angiogenesis and EMT.21
Increased plasma TGF-β1 negatively correlates with 
survival in patients with SCCHN who received cetuximab- 
based therapy.22 Furthermore, there is a link between 
dysregulation of TGF-β signaling and the development of 
HPV- positive tumors,23–25 and HPV status is a prognostic 
biomarker in SCCHN.26 Consequently, it is possible that 
dysregulation of TGF-β signaling may drive tumorigen-
esis in HPV- positive cancers. Virus- associated cancers are 
more likely to be immunologically inflamed and thus 
susceptible to immunotherapy- based treatments.27 There-
fore, sequestering TGF-β from the tumor microenviron-
ment while simultaneously inhibiting the PD- L1 immune 
checkpoint may provide a novel treatment approach.
Bintrafusp alfa (M7824) is a first- in- class bifunctional 
fusion protein composed of the extracellular domain of 
the human TGF-β receptor II (TGF-βRII or TGF-β ‘trap’) 
fused via a flexible linker to the C- terminus of each heavy 
chain of an IgG1 antibody blocking PD- L1 (anti- PD- L1).28 
Preclinical studies in murine models showed that bintra-
fusp alfa more effectively suppressed tumor growth and 
metastasis than either a TGF-β trap or an anti- PD- L1 anti-
body alone.29 Bintrafusp alfa also inhibited spontaneous 
metastasis in multiple preclinical models,29 30 presum-
ably due to its suppressive effect on EMT. Data from a 
phase I, dose- escalation study suggested that bintrafusp 
alfa—administered at doses of up to 20 mg/kg—had a 
manageable safety profile and showed early signs of clin-
ical efficacy in patients with heavily pretreated advanced 
solid tumors.28 Bintrafusp alfa also showed activity in 
patients with HPV- associated malignancies, including 
cervical cancer, anal cancer and SCCHN.31 Here, we 
report the efficacy and safety results of a phase I trial of 
bintrafusp alfa monotherapy in patients with advanced 
SCCHN that progressed after the last dose of platinum- 
based therapy.
Methods
study design and participants
NCT02517398 is an ongoing, phase I, open- label trial 
of bintrafusp alfa that includes multiple solid tumor 
expansion cohorts. Planned enrollment for the advanced 
SCCHN cohort was 30 patients. With 30 subjects treated, 
the study has approximately 87% power to rule out a 
≤15% ORR (null hypothesis) when the true ORR is 35% 
at the 10% type I error rate (one- sided). Meeting this 
endpoint would have warranted the clinical development 
of a phase II or III trial based on a very strong phase I 
signal. Eligible patients were aged ≥18 years and had 
histologically confirmed, advanced SCCHN not amenable 
to curative therapy that progressed/recurred after prior 
platinum therapy in the recurrent/metastatic setting, or 
within 6 months after the last dose of platinum received 
in combination with radiotherapy for the treatment 
of locally advanced disease. Patients may have received 
prior cetuximab, but prior treatment with any antibody/
drug- targeting T- cell coregulatory proteins such as anti- 
PD-1, anti- PD- L1 or anticytotoxic T- lymphocyte- associated 
protein-4 antibody was not allowed. Patients had an 
Eastern Cooperative Oncology Group performance status 
of 0 or 1; life expectancy of ≥12 weeks; adequate renal, 
hepatic and hematological function; measurable disease 
by RECIST 1.1 and available archival tumor material or 
fresh biopsies taken within 28 days of the first administra-
tion of study drug. Patients were not selected on the basis 
of PD- L1 expression or other biomarkers.
Procedures
Integrated analysis of bintrafusp alfa exposure, response 
and progression- free survival (PFS) supported a flat dose 
of 1200 mg every 2 weeks,32 and this dose was used in 
the expansion cohorts. Patients received bintrafusp alfa 
via intravenous infusion over 1 hour once every 2 weeks 
until confirmed progressive disease (PD), unacceptable 
toxicity or trial withdrawal. Treatment beyond PD was 
permitted if adverse events (AEs) were manageable, 
performance status was maintained, and no further treat-
ment was indicated.
Premedication with an antihistamine and acetamin-
ophen approximately 30–60 min prior to each dose of 
bintrafusp alfa was mandatory for the first 2 infusions 
and was optional afterward. Dose reduction was not 
permitted; however, interruption or discontinuation of 
bintrafusp alfa was allowed as described in online supple-
mentary table S2.
Tumor response was assessed by radiographic imaging 
6 weeks after initiating treatment, then every 6 weeks for 
the first year and every 12 weeks thereafter. Response 
was confirmed by repeated radiographic assessment no 
sooner than 4 weeks from the first documentation of 
response. AEs were monitored throughout treatment, for 
the first 28 days after the last study dose, at 10 weeks post- 
treatment and every 12 weeks thereafter and were assessed 
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were identified using a prespecified list of MedDRA 
preferred terms followed by medical review.
outcomes
The primary endpoint for this expansion cohort was 
to assess the confirmed best overall response (BOR) 
according to RECIST 1.1 as adjudicated by an indepen-
dent review committee (IRC). Secondary endpoints 
included BOR per investigator and safety and tolerability. 
Exploratory endpoints included PFS, duration of response 
(DOR) and disease control rate (DCR) according to 
RECIST 1.1 as adjudicated by IRC, and OS. Exploratory 
biomarker analyses of efficacy were also performed.
statistical analysis
Efficacy and safety were analyzed in all patients who 
received ≥1 dose of bintrafusp alfa. DCR—defined as the 
proportion of patients with a BOR of complete response 
(CR), partial response (PR), non- CR/non- PD or stable 
disease (SD) —was tabulated with an exact 95% Clopper- 
Pearson CI. PFS, DOR and OS were analyzed using 
the Kaplan- Meier method. Safety and tolerability were 
analyzed using descriptive statistics.
biomarker analyses
Tumor PD- L1 protein expression was measured by immu-
nohistochemical staining of formalin- fixed, paraffin- 
embedded (FFPE) tumor tissue blocks using a proprietary 
assay (Dako, Carpinteria, California, USA) and an anti- 
PD- L1 rabbit monoclonal antibody clone 73-10 under 
license from Merck KGaA (Darmstadt, Germany). PD- L1 
positivity in tumor cells was scored as the proportion of 
tumor cells showing membranous PD- L1 staining.
HPV status was determined by RNA sequencing 
(RNASeq) using FFPE tissue samples and standard proto-
cols. Kallisto33 (V.0.43.1) was used to align sequencing 
results to a transcriptome containing the human Ensembl 
transcripts (V.91, GRCh38) and viral genomes from the 
National Center for Biotechnology Information collec-
tion. HPV content in each sample was assessed as the frac-
tion of reads mapping to any papillomavirus genome. To 
determine a cut- off (for fraction of viral reads), the same 
process was applied to SCCHN samples from SRP063006/
GSE72536 and SRP066090/GSE74927. The HPV statuses 
deposited with these sequences were used to choose a cut- 
off that provided perfect separation between the 28 posi-
tive and 51 negative training samples.
For gene expression quantification, RNASeq data were 
generated from FFPE tissue samples and standard proto-
cols. Bowtie2 V.2.2.334 was used to align sequencing results 
to the Ensembl 75 human genome (GRCh37 February 
2014). Gene expression was determined using RSEM 
V.1.2.31 with the Ensembl gene annotations.35 Hypothesis 
testing was performed by comparing RSEM- computed 
expected counts. Transcript- per- million (TPM) values 
were upper- quartile normalized and log- transformed 
for further analysis. Signature scores were defined as the 
mean log 2 (fold- change) among all genes in each gene 
signature (online supplementary table S3).19 36 These 
were calculated by adding a pseudocount of 0.5 TPM to 
all genes and samples, determining the log 2 (TPM), then 
subtracting the median log 2- TPM for each gene across 
all samples from the log 2- TPM for each gene.
Tumor samples were used to determine immune 
phenotype based on available immunohistochemistry 
data (PD- L1 stain and PD- L1 negative control) and H&E 
staining. An exploratory classification system was used 
to categorize tumors as having an immune- inflamed 
(immune cells in direct physical contact with tumor cells), 
immune- excluded (≥1% of tumor stroma area populated 
by lymphocytes, immune cells possibly located in imme-
diate vicinity of tumor cells but not efficiently infiltrating 
tumor cell clusters, and very infrequent physical contact 
between lymphocytes and tumor cells), or immune desert 
(<1% of tumor stroma area populated by lymphocytes, no 
dense immune cell infiltrates and no contact of immune 
cells with tumor cells) phenotype. This system was devel-
oped from methods previously described.19 A pathologist 
who was masked to the response data scored the scanned 
slides and determined the corresponding immune 
phenotype.
results
Patient population and baseline characteristics
Between October 6, 2016 and January 12, 2017, 46 
patients were screened. Of these, 32 patients were 
enrolled and treated (full analysis set) at 20 sites in 
the Asia- Pacific region, Europe and the USA. At the 
time of data cut- off on August 24, 2018, patients had 
been followed for a median of 86.4 weeks (range 2–97 
weeks); 4 patients (13%) remained on treatment and 
the median duration of therapy was 12.1 weeks (range 
2–96 weeks). The primary reason for treatment discon-
tinuation was disease progression (n=20 (63%)), AE 
(n=5 (16%)), consent withdrawal (n=1 (3%)), death 
unrelated to study treatment (hemorrhage; n=1 (3%)) 
and investigator decision (n=1 (3%)). The death unre-
lated to study treatment occurred 2 weeks after the 
patient received the first and only dose of bintrafusp 
alfa. Twenty- eight patients (88%) had progressed on 
platinum- based therapy in the second- line or later- line, 
recurrent and/or metastatic setting, and 4 patients 
(13%) had progressed on platinum- based therapy in 
the locally advanced setting (table 1).
efficacy
The confirmed ORR by IRC was 13% (95% CI 4% 
to 29%; 4 PR), and an additional 4 patients had SD, 
resulting in a DCR of 25% (95% CI 12% to 43%) (table 2 
and figure 1A,B). The median DOR was 18.1 months 
(range 6–20+ months). Two of 4 patients with PR had an 
ongoing response of 16.5+ and 19.6+ months as of data 
cut- off (figure 1C). Median PFS was 1.4 months (95% 
CI 1.3 to 4.0 months) and the 6- month and 12- month 
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Table 1 Patient demographics and baseline characteristics
Characteristic N=32
Sex
  Male 27 (84)
  Female 5 (16)
Age, years
  Median (IQR) 60 (53–65)
  <65 22 (69)
  ≥65 10 (31)
Primary tumor site
  Oral cavity 11 (34)
  Oropharynx 7 (22)
  Hypopharynx 4 (13)
  Larynx 4 (13)
  Nasal cavity and sinuses 2 (6)
  Nasopharynx 1 (3)
  Other* 3 (9)
Number of prior anticancer therapies
  1 8 (25)
  2 11 (34)
  ≥3 13 (41)
Prior anticancer therapy setting
  For locally advanced disease only 4 (13)




  0 7 (22)
  1 25 (78)
PD- L1 expression
  <1% tumor cells 6 (19)
  ≥1% tumor cells 25 (78)
  Not evaluable 1 (3)
HPV status
  Positive 9 (28)
  Negative 22 (69)
  Not evaluable 1 (3)
Prior cetuximab
  Yes 24 (75)
  No 8 (25)
Data are number (%) unless stated otherwise.
*Tonsil, pharynx and larynx and tongue (n=1 each (3%)).
ECOG, Eastern Cooperative Oncology Group; HPV, human 
papillomavirus; PD- L1, programmed death- ligand 1.







Confirmed BOR, n (%)
  CR 0 0
  PR 4 (13) 5 (16)
  SD 4 (13) 6 (19)
  Non- CR/non- PD* 3 (9) –
  PD 19 (59) 18 (56)
  Not evaluable 2 (6)† 3 (9)‡
Confirmed ORR (95% CI), 
%
13 (4 to 29) 16 (5 to 33)
Total clinical response rate 
(95% CI), %§
16 (5.3 to 32.8) 22 (9.3 to 40)
DCR (95% CI), % 25 (12 to 43) 34 (19 to 53)
Median PFS (95% CI), 
months
1.4 (1.3 to 4.0) 1.4 (1.3 to 
3.9)
PFS rate (95% CI), %
  6- month 28 (14 to 45) 21 (9 to 37)
  12- month 21 (9 to 37) 17 (6 to 33)
  18- month 21 (9 to 37) 17 (6 to 33)
*Persistence of 1 or more non- target lesion(s) and/or maintenance 
of tumor marker level above the normal limits.
†No IRC review due to no postbaseline assessments.
‡No postbaseline assessments due to death within 6 weeks 
after start date; no postbaseline assessments; SD (or better) of 
insufficient duration (<6 weeks after start date without further 
evaluable tumor assessment) (n=1 each).
§Defined as the proportion of patients with CR, PR and delayed PR 
after initial PD.
BOR, best overall response; CR, complete response; DCR, 
disease control rate; IRC, independent review committee; NE, not 
estimable; ORR, objective response rate; PD, progressive disease; 
PFS, progression- free survival; PR, partial response; SD, stable 
disease.
(95% CI 9% to 37%), respectively; the 18- month PFS 
rate was stable at 21% (table 2 and figure 2A). Median 
OS was 9.1 months (95% CI 6.6 months to not estimable 
(NE)) and the 12- month and 18- month OS rates were 
48% (95% CI 30% to 64%) and 44% (95% CI 26% to 
61%), respectively (figure 2B).
By investigator assessment, ORR and DCR were 16% 
and 34%, respectively (table 2). Two patients devel-
oped delayed PR after initial PD (time to PR 5.1 and 8.5 
months); the patient with time to PR of 8.5 months by 
investigator assessment did not have target lesions and 
was therefore assessed as non- CR/non- PD by IRC based 
on the non- target lesions. The total clinical response rate 
by investigator assessment was 22%.
safety and tolerability
Thirty- one patients (97%) experienced a treatment- 
emergent AE (TEAE) and 24 (75%) experienced a grade 
≥3 TEAE. Treatment was discontinued in 8 patients 
(25%) due to TEAE. Twenty- two patients (69%) expe-
rienced treatment- related AEs (TRAEs); of these, 11 
(34%) experienced grade 3 TRAEs, which included rash 
maculopapular (n=2 (6%)) and increased liver enzymes, 
anemia, diabetic ketoacidosis, colitis, hyperglycemia and 
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Figure 2 PFS (A) and OS (B) in all patients. NE, not 
estimable; OS, overall survival; PFS, progression- free 
survival.
Figure 1 Tumor regression from baseline (A and B) and 
time to and duration of response (C) in the full analysis set . 
CR, complete response; NE, not estimable; PD, progressive 
disease; PR, partial response; SD, stable disease. *Delayed 
PR after initial PD.
4 or 5 TRAEs were observed. TRAEs led to treatment 
discontinuation in 2 patients (colitis and SCC of the skin 
n=1 each (6%)). Keratoacanthomas (n=3 (9%)) and SCC 
of the skin (n=2 (6%)) were managed with excision and 
observation. No patient experienced an infusion- related 
reaction and no infusion rate reductions were necessary. 
Immune- related AEs were observed in 13 patients (41%), 
and 4 experienced grade 3 immune- related AEs (colitis 
and increased alanine and aspartate aminotransferases 
(n=1 each) and rash maculopapular (n=2)); no grade 4 
or 5 immune- related AEs were observed (online supple-
mentary table S4). The occurrence of immune- related 
colitis led to treatment discontinuation in 1 patient (3%).
biomarker analysis
Tumor PD- L1 expression status was available in 31 of 32 
patients. Of 25 patients with PD- L1 expression on ≥1% 
of tumor cells (PD- L1- positive), 3 achieved PR and 3 had 
SD, resulting in an ORR of 12% (95% CI 3% to 31%) 
and DCR of 24% (95% CI 9% to 45%). One of 6 patients 
with PD- L1 expression on <1% of tumor cells (PD- L1- 
negative) achieved PR (figure 3A and online supplemen-
tary table S5). Median PFS in patients with PD- L1- positive 
tumors was 1.4 months (95% CI 1.2 to 4.0 months) and 
3.5 months (95% CI 1.2 months to NE) in patients with 
PD- L1- negative tumors (figure 3B and online supplemen-
tary table S5). Median OS in patients with PD- L1- positive 
tumors was 8.8 months (95% CI 6.3 months to NE) and 
NE (95% CI 3.2 months to NE) in patients with PD- L1- 
negative tumors (figure 3C and online supplementary 
table S5).
Tumor HPV status was evaluable in 31 of 32 patients. 
Objective responses were observed in 3 of 9 patients with 
HPV- positive tumors (33% (95% CI 5% to 70%)) and 
in 1 of 22 patients with HPV- negative tumors (5% (95% 
CI 0% to 23%)) (figure 3D, online supplementary table 
S1 and online supplementary figure S1). Median PFS in 
patients with HPV- positive tumors was 2.7 months (95% 
CI 1.2 to 19.6 months) and 1.3 months (95% CI 1.2 to 4.0 
months) in patients with HPV- negative tumors. Median 
OS in patients with HPV- positive tumors was 8.0 months 
(95% CI 2.7 months to NE) and 9.1 months (95% CI 
6.3 months to NE) in patients with HPV- negative tumors 
(online supplementary table S1 and online supplemen-
tary figure S1).
A total of 30 patients had both HPV and PD- L1 data 
available. Among 9 patients with HPV- positive tumors, 7 
(78%) were PD- L1- positive, and among 21 patients with 
HPV- negative tumors, 17 (81%) were PD- L1- positive, 
suggesting no association between HPV status and PD- L1 
expression.
RNAseq data were analyzed to evaluate prespecified 
genes and gene signatures related to the TGF-β pathway 
and the immune- related pathways versus response to 
bintrafusp alfa. An extensive exploratory analysis was also 
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Table 3 TRAEs of any grade in ≥2 patients or any grade 3 
events in any patient (N=32)
Any grade Grade 3
Patients with any TRAE 22 (69) 11 (34)
  Asthenia 5 (16) 0
  Hypothyroidism 5 (16) 0
  Pruritus 5 (16) 0
  Rash maculopapular 5 (16) 2 (6)
  ALT increased 4 (13) 1 (3)
  AST increased 4 (13) 1 (3)
  Stomatitis 3 (9) 0
  Anemia 2 (6) 1 (3)
  Decreased appetite 2 (6) 0
  Diarrhea 2 (6) 0
  Fatigue 2 (6) 0
  Musculoskeletal pain 2 (6) 0
  Hyperthyroidism 2 (6) 1 (3)
  Colitis 1 (3) 1 (3)
  Diabetic ketoacidosis 1 (3) 1 (3)
  Hyperglycemia 1 (3) 1 (3)
  Hyperkeratosis follicularis and 
parafollicularis
1 (3) 1 (3)
  GGT increased 1 (3) 1 (3)
  Lipase increased 1 (3) 1 (3)
Skin lesions* 4 (13) 2 (6)
  Keratoacanthoma 3 (9) 1 (3)
  SCC of skin 2 (6) 1 (3)
Data are number (%) unless otherwise stated.
*Includes MedDRA V.21.0 preferred terms ‘SCC of skin’, ‘basal 
cell carcinoma’, ‘keratoacanthoma’, ‘hyperkeratosis’ and ‘actinic 
keratosis’. In addition to those shown, 1 patient who reported 
keratoacanthoma and SCC of skin (as above) also reported grade 
2 actinic keratosis and grade 2 basal cell carcinoma.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
GGT, gamma- glutamyltransferase; SCC, squamous cell carcinoma; 
TRAE, treatment- related adverse event.
with response to bintrafusp alfa in a biology/pathway 
agnostic manner. Several genes and signatures that reflect 
immune activity had higher levels in HPV- positive tumors 
compared with HPV- negative tumors, although the differ-
ences were not statistically significant after correcting for 
the size of the set tested (figure 3E).
Evaluable patient tumors were characterized according 
to immune phenotype as either inflamed (tumor infiltra-
tion of both CD4+ and CD8+ T cells and other immune 
cells), immune- excluded (immune cells are present but 
do not infiltrate the tumor) or immune- desert (lack 
of immune cells in and around the tumor). Of the 10 
patients with a tumor of the inflamed immune pheno-
type, 4 had responses, and of 21 patients with a tumor 
of the immune- excluded phenotype, 5 had responses. A 
response following pseudoprogression was observed in a 
patient with a tumor of the immune- excluded phenotype 
(figure 3F).
disCussion
In this pretreated population of patients with advanced 
SCCHN, bintrafusp alfa monotherapy showed clin-
ical activity, with an ORR of 16% and DCR of 34% per 
investigator, a 44% OS rate at 18 months and a median 
DOR (mDOR) of 18.1 months. These preliminary results 
are comparable to those in similar patient populations 
treated with the anti- PD-1 immune checkpoint inhibitors 
pembrolizumab and nivolumab, with ORRs of 13% to 
18% and mDORs of 8–18.4 months in previously treated 
patients with PD- L1- unselected tumors.4 7 17 37 38 Bintra-
fusp alfa also had a manageable safety profile. Poten-
tial TGF-β-related AEs (eg, keratoacanthoma) were well 
managed with simple excision and observation and did 
not result in trial discontinuation. No recurrence of kera-
toacanthoma or SCC has been reported. The incidence, 
severity and type of immune- related AEs observed with 
bintrafusp alfa were comparable to those seen with anti- 
PD- L1 agents.4 7 17 37
Bintrafusp alfa monotherapy showed activity irrespec-
tive of tumor PD- L1 expression. DCRs in patients with 
PD- L1- positive and PD- L1- negative tumors were 24% 
and 33% and 18- month OS rates were 40% and 50%, 
respectively. We also observed numerically higher ORR in 
patients with HPV- positive tumors (33%) compared with 
patients with HPV- negative tumors (5%). A separate study 
found that bintrafusp alfa stimulated an HPV- specific 
response,31 suggesting that bintrafusp alfa may have 
additional activity in HPV- positive disease. This obser-
vation may be due to the link between TGF-β signaling 
and HPV- positive tumors and to the greater inflammatory 
immune response generally observed in virus- associated 
cancers.23–25 27 Indeed, a retrospective subgroup analysis 
of the dose- finding cohort of this phase I trial revealed 
an ORR of 46% in 11 patients with HPV- positive cancers 
(mixed cohort of patients with cervical, anal and SCCHN 
tumors) receiving bintrafusp alfa monotherapy adminis-
tered at doses of 0.3–30 mg/kg, with durable and ongoing 
responses.31 Furthermore, while responses to PD- L1 
agents are generally observed in inflamed immune micro-
environments,39 patients who achieved objective response 
or disease control in this study had tumors with either an 
inflamed or immune- excluded immune phenotype.
Thus, bifunctional targeting of the TGF-β and PD- L1 
pathways with bintrafusp alfa may be an encouraging 
approach for patients with advanced SCCHN and in HPV- 
associated cancers. Bintrafusp alfa is being evaluated in 
phase I and II trials, including the phase II NCT03427411 
study, which is specifically enrolling patients with HPV- 
associated malignancies, such as cervical cancer, p16+ 
oropharyngeal SCCHN and anogenital cancers, including 
vaginal, vulvar, anal and penile carcinomas.
A preclinical study investigated the link between TGF-β 
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Figure 3 Tumor regression from baseline (A, D), PFS (B) and OS (C) according to tumor PD- L1 expression and HPV status, 
respectively, and gene expression profiling status (E) and immune phenotype (F). BOR, best overall response; CR, complete 
response; HPV, human papillomavirus; IFN-γ, interferon-γ; NE, not estimable; NK, natural killer; OS, overall survival; PD, 
progressive disease; PD- L1, programmed death- ligand 1; PFS, progression- free survival; PR, partial response; SD, stable 
disease; Teff, effector T cell; VIM, vimentin. *Delayed PR after initial PD.
of several genes and antitumor activity.30 Genes related to 
both pathways targeted by bintrafusp alfa (natural killer 
cell signature, effector T- cell signature, CD8A, CD8B, 
interferon-γ signature, TGFB1, TWIST1 and VIM) were 
examined in archival tumor samples using RNASeq; 
these data were found to be consistent with HPV- positive 
tumors having more pre- existing immune response.
The single- arm design of this study is a potential limita-
tion, making it difficult to compare these results with 
those in patients treated with chemotherapy or estab-
lished immune checkpoint inhibitors. Furthermore, the 
small sample sizes of subgroups (eg, for the HPV- positive 
cohort (n=9) and PD- L1- negative cohort (n=6)) limit 
conclusions. Nevertheless, the results in this expansion 
cohort warrant further investigation of bintrafusp alfa in 
advanced SCCHN.
ConClusions
In summary, bintrafusp alfa monotherapy showed clinical 
activity and had a manageable safety profile in this phase 
I cohort of patients with heavily pretreated, advanced 
SCCHN with limited or no available therapeutic options. 
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